Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Peter A. Altman
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 17
- Beta
- 0.49
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -50.71
Financials
Revenue
$0.00-100.0%Net Income
$-1.61M-131.5%EBITDA
$-1.49M-129.1%Free Cash Flow
$-1.74M-131.2%EPS (diluted)
$-0.13-100.1%Shares Outstanding (diluted)
12.09M+28349.4%Operating Expenses
$1.62MCash & Debt
$4.12MRevenue by Segment (annual)
$477.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-8.23M | $-1.23 |
| 2024 | $58.0K | $-7.95M | $-2.90 |
| 2023 | $477.0K | $-11.57M | $-8.19 |
| 2022 | $1.35M | $-11.91M | $-10.05 |
| 2021 | $1.01M | $-12.62M | $-11.19 |
| 2020 | $145.0K | $-15.00M | $-22.20 |
| 2019 | $710.0K | $-14.71M | $-39.15 |
| 2018 | $625.0K | $-13.99M | $-48.80 |
| 2017 | $479.0K | $-12.31M | $-43.50 |
| 2016 | $576.0K | $-10.31M | $-166.33 |
| 2015 | $517.0K | $322.0K | $27.86 |
| 2014 | $427.0K | $234.0K | $20.50 |
| 2013 | $268.0K | $19.0K | $0.13 |
| 2012 | $62.0K | $305.0K | $28.61 |
Valuation
BCDAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-16.67%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·5d ago·Neutral
BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter SUNNYVALE, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported it has completed its revised Pre-Submission to FDA Center for Devices and Radiological Health (CDRH) under its Q-Submission program for the approval of its Helix Catheter (“Helix”) for therapeutic a…
View source ↗ - Newsglobenewswire.com·13d ago·Negative
BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission SUNNYVALE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an update on near term milestones.
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
…ory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference SUNNYVALE, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that Peter Altman, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will be held at the Lotte New York …
View source ↗ - Newsglobenewswire.com·43d ago·Neutral
…very Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval SUNNYVALE, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces receipt of FDA confirmation of the outcome of its Pre-Submission Meeting on the Helix Transendocardial Delivery Catheter System (Helix).
View source ↗ - Newsseekingalpha.com·54d ago·Positive
BioCardia, Inc. (BCDA) Q2 2026 Earnings Call Transcript BioCardia, Inc. (BCDA) Q2 2026 Earnings Call Transcript
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.15 per share
Typical surprise +4.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.13 vs $-0.18beat
- Fri, May 15$-0.21 vs $-0.17miss
- Tue, Mar 24$-0.06 vs $-0.20beat
- Wed, Nov 12$-0.24 vs $-0.25beat
- Mon, Aug 11$-0.40 vs $-0.25miss
- Wed, May 14$-0.59 vs $-0.39miss
Estimates and results for BCDA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BCDA officers and directors.
- Bought
- $3.9m
- Sold
- —
69 trades
0 trades
- Altman Peterbought
- Altman Peterbought
- Altman Peterbought
- Altman Peterbought
- Altman Peterbought
- Altman Peterbought
- Altman Peterbought
- Altman Peterbought
31 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BCDA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.